natgillin/translations-raw huggingface dataset:
Single use vials.
Viale za enkratno uporabo.
Vials containing 20 mg/1 ml, 80 mg/4 ml, 120 mg/6 ml, 140 mg/7 ml and 160 mg/8 ml are available in packs containing a single vial.
Viale, ki vsebujejo 20 mg/1 ml, 80 mg/4 ml,120 mg/6 ml, 140 mg/7 ml in 160 mg/8 ml so na voljo v škatlah, ki vsebujejo po eno vialo.
• 1,312 and 121 patients who received 100 mg/m2 and 75 mg/m2 of docetaxel as a single agent
• 1.312 bolnikih, ki so v monoterapiji prejemali 100 mg/m² docetaksela, 121 pa jih je prejemalo
This is equivalent to 10 ml of beer or 4 ml of wine.
To ustreza 10 ml piva ali 4 ml vina.
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds which induce, inhibit or are metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450-3A such as ciclosporine, ketoconazole and erythromycin.
Študije in vitro so pokazale, da lahko presnovo docetaksela spremeni sočasna uporaba zdravil, ki inducirajo ali inhibirajo citokrom P450-3A ali se z njim presnavljajo (in ga tako lahko kompetitivno inhibirajo), kot so ciklosporin, ketokonazol in eritromicin.Zato je med sočasnim zdravljenjem s temi zdravili potrebna previdnost, saj obstaja možnost pomembnega medsebojnega delovanja.
160mg/8 ml contains 8 ml of concentrate.
160 mg/8 ml vsebuje 8 ml koncentrata.
• nasal drainage; inflammation of the throat and nose; cough
• izcedek iz nosu, vnetje žrela in nosu, kašelj
If Taxespira concentrate should come into contact with mucous membranes, wash immediately and thoroughly with water.
Če pride koncentrat zdravila Taxespira v stik s sluznicami, jih je treba takoj in temeljito umiti z vodo.
G3/4 Blood alkaline phosphatase increased
zvečanje alkalne fosfataze v krvi S3/4
• Induction chemotherapy followed by radiotherapy (TAX323) The safety and efficacy of docetaxel in the induction treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a phase III, multicenter, open-label, randomized study (TAX323).
• Indukcijska kemoterapija in nato radioterapija (TAX323) Varnost in učinkovitost zdravila docetaksel za indukcijsko zdravljenje bolnikov s skvamoznoceličnim karcinomom glave in vratu (SCCHN) so ocenjevali v multicentrični odprti randomizirani študiji faze III (TAX323).
140mg/7 ml contains 7 ml of concentrate.
140 mg/7 ml vsebuje 7 ml koncentrata.
At the median follow-up time of 77 months, OS was longer in the TAC arm with TAC-treated patients having a 24% reduction in the risk of death compared to FAC (hazard ratio = 0.76, 95% CI (0.46-1.26, p = 0.29).
Po mediano 77 mesecih spremljanja je bilo tudi celokupno preživetje v kraku TAC daljše: tveganje za smrt je bilo med prejemnicami TAC za 24 % manjše kot med prejemnicami FAC (razmerje ogroženosti = 0,76, 95 % IZ 0,46-1,26, p = 0,29).
5.1 Pharmacodynamic properties
5.1 Farmakodinamičnelastnosti
Therefore, the recommended dose of docetaxel in those patients with elevated liver function test (LFTs) is 75 mg/m2 and LFTs should be measured at baseline and before each cycle (see section 4.2).
Zato je pri bolnikih z zvišanimi vrednostmi testov jetrne funkcije priporočeni odmerek docetaksela 75 mg/m2, teste jetrne funkcije pa je treba opraviti na začetku in pred vsakim ciklusom zdravljenja (glejte poglavje 4.2).
20mg/1 ml contains 1 ml of concentrate.
20 mg/1 ml vsebuje 1 ml koncentrata.
256 patients were randomised to treatment with docetaxel alone (100 mg/m2 as a 1 hour intravenous infusion every 3 weeks).
256 bolnic so randomizirali na zdravljenje z docetakselom samim (100 mg/m2 v 1-urni intravenski infuziji na
There was less use of morphinic analgesic (p <0.01), non-morphinic analgesics (p <0.01), other disease-related medicinal products (p = 0.06) and radiotherapy (p <0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Bolniki, zdravljeni z docetakselom v odmerku 75 mg/m2, so rabili manj morfinskih analgetikov (p < 0,01), nemorfinskih analgetikov (p < 0,01), drugih z boleznijo povezanih zdravil (p = 0,06) in radioterapije (p < 0,01) kot tisti, ki so bili deležni najboljše podporne oskrbe.
Thrombocytopenia (G3/4: 0.6%); Febrile neutropenia
trombocitopenija, (S3/4: 0,6 %), febrilna nevtropenija
Ear and labyrinth disorders Rare cases of ototoxicity, hearing impaired and/or hearing loss have been reported.
Ušesne bolezni, vključno z motnjami labirinta Opisani so bili redki primeri ototoksičnosti, okvar sluha in/ali poslabšanja sluha.
For prostate cancer, given the concurrent use of prednisone or prednisolone the recommended premedication regimen is oral dexamethasone 8 mg, 12 hours, 3 hours and 1 hour before the docetaxel infusion (see section 4.4).
Pri zdravljenju raka prostate, v primeru sočasne uporabe prednizona ali prednizolona, je priporočena premedikacija peroralni deksametazon 8 mg, 12 ur, 3 ure in 1 uro pred infuzijo docetaksela (glejte poglavje 4.4).
In chemotherapy naïve patients treated for non-small cell lung cancer, the recommended dose regimen is docetaxel 75 mg/m immediately followed by cisplatin 75 mg/m over 30-60 minutes.
Pri bolnikih z nedrobnoceličnim pljučnim rakom, ki še niso bili zdravljeni s kemoterapijo, je priporočena shema odmerjanja docetaksel v odmerku 75 mg/m2, ki mu takoj sledi cisplatin v odmerku 75 mg/m apliciran 30-60 minut.
50 mg/m2 (TAC arm), or doxorubicin 50 mg/m 2 followed by fluorouracil 500 mg/m2 (FAC arm).
mg/m2, ki sta mu sledila fluorouracil 500 mg/m2 in ciklofosfamid 500 mg/m2 (krak FAC).
In alkylating-failure patients, docetaxel was compared to doxorubicin (75 mg/m² every 3 weeks).
Pri bolnicah z neuspelim alkilirajočim zdravljenjem so docetaksel primerjali z doksorubicinom (75 mg/m na 3 tedne).
• ventricular arrhythmia or ventricular tachycardia (manifested as irregular and/or rapid heartbeat,
• prekatne motnje srčnega ritma ali prekatna tahikardija (ki se kaže z nerednim in/ali hitrim bitjem srca, zelo težkim dihanjem, omotico in/ali omedlevico).
75 mg/m2, as a 1- to 3-hour infusion (both on day 1 only), followed by 5-fluorouracil 750 mg/m2 per day given as a 24-hour continuous infusion for 5 days, starting at the end of the cisplatin infusion.
urni infuziji (oboje samo 1. dan); temu sledi 5-fluorouracil 750 mg/m2 na dan v 24-urni stalni infuziji 5 dni, z začetkom ob koncu infuzije cisplatina.
Taxespira in combination with capecitabine
Zdravilo Taxespira v kombinaciji s kapecitabinom
In combination with cisplatin and 5-fluorouracil for the treatment of patients with gastric adenocarcinoma, the pivotal clinical study excluded patients with ALT and/or AST >1.5 × ULN associated with alkaline phosphatase >2.5 × ULN, and bilirubin >1 x ULN; for these patients, no dose-reductions can be recommended and docetaxel should not be used unless strictly indicated.
V ključni klinični študiji docetaksela v kombinaciji s cisplatinom in 5-fluorouracilom pri bolnikih z adenokarcinomom želodca so izključili bolnike z ALT in/ali AST > 1,5 x ULN ter hkrati alkalno fosfatazo > 2,5 x ULN in bilirubinom > 1 x ULN; pri teh bolnikih ni mogoče priporočiti zmanjšanja odmerka in docetaksela se ne sme uporabljati, če ni strogo indiciran.
140mg/7 ml Each 7 ml vial of concentrate contains 3.5 ml of ethanol anhydrous (2765 mg).
140 mg/7 ml Ena 7 ml viala koncentrata vsebuje 3,5 ml brezvodnega etanola (2765 mg).
For breast, non-small cell lung, gastric, and head and neck cancers, premedication consisting of an oral corticosteroid, such as dexamethasone 16 mg per day (e.g. 8 mg BID) for 3 days starting 1 day prior to docetaxel administration, unless contraindicated, can be used (see section 4.4).
Pri zdravljenju raka dojke, nedrobnoceličnega pljučnega raka, raka želodca ter raka glave in vratu lahko kot premedikacijo dajemo peroralne kortikosteroide, kot je deksametazon 16 mg na dan (npr. 8 mg dvakrat dnevno) v trajanju treh dni, in sicer 1 dan pred aplikacijo docetaksela, razen v primeru kontraindikacij (prosimo, glejte poglavje 4.4).
Acute respiratory distress syndrome and cases of interstitial pneumonia/pneumonitis, interstitial lung disease, pulmonary fibrosis and respiratory failure sometimes fatal have rarely been reported.
Bolezni dihal, prsnega koša in mediastinalnega prostora V redkih primerih so bili opisani akutni respiracijski distres sindrom in primeri intersticijske pljučnice/pnevmonitis, intersticijska bolezen pljuč, pljučna fibroza in dihalna odpoved, ki so bili včasih usodni.
Description of selected adverse reactions for adjuvant therapy with Taxespira 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis izbranih neželenih učinkov adjuvantnega zdravljenja z zdravilom Taxespira 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805)
Dizziness; Headache (G3/4: <1%); Neuropathy peripheral
Bolezni živčevja omotica, glavobol (S3/4: < 1 %), periferna nevropatija
Each ml of concentrate contains 20 mg docetaxel (as trihydrate).
En ml koncentrata vsebuje 20 mg docetaksela (v obliki trihidrata).
In study TAX316 alopecia persisting into the follow-up period after the end of chemotherapy was reported in 687 of 744 TAC patients (92.3%) and 645 of 736 FAC patients (87.6%).
V študiji TAX316 je alopecija trajala še naprej v obdobju spremljanja po koncu kemoterapije pri 687 od 744 bolnic, ki so prejemale TAC (92,3 %), in pri 645 od 736 bolnic, ki so prejemale FAC (87,6 %).
For more details see summary of product characteristics of trastuzumab.
Za nadaljnje podrobnosti prosimo, glejte povzetek glavnih značilnosti trastuzumaba.
One large randomized phase III study, involving 429 previously untreated patients with metastatic disease, has been performed with doxorubicin (50 mg/m²) in combination with docetaxel (75 mg/m²) (AT arm) versus doxorubicin (60 mg/m²) in combination with cyclophosphamide (600 mg/m²) (AC arm).
Zdravilo Taxespira v kombinaciji z doksorubicinom Opravljena je bila ena velika randomizirana študija III. faze, ki je vključevala 429 predhodno nezdravljenih bolnic z metastatsko boleznijo; v njej so kombinacijo doksorubicina (50 mg/m2) in docetaksela (75 mg/m 2) (krak AT) primerjali s kombinacijo doksorubicina (60 mg/m 2) in ciklofosfamida
Adjuvant radiation therapy was administered according to guidelines in place at participating institutions and was given to 57.3 % of patients who received TAC and 51.2 % of patients who received FAC.
Dobilo jo je 57,3% bolnic, ki so prejemale TAC, in 51,2% bolnic, ki so prejemale FAC.
Alopecia; Nail disorders (severe: 0.4%); Skin reaction (no severe)
Bolezni kože in podkožja alopecija, spremembe nohtov (hude 0,4 %), kožna reakcija (nobene hude)
• pulmonary fibrosis (scarring and thickening in the lungs with shortness of breath)
• plučna fibroza (brazgotinjenjein zadebelitve v pljučih, težko dihanje/kratkasapa)
A total of 445 patients with KPS >70 were treated with either docetaxel (T) (75 mg/m2 on day 1) in combination with cisplatin (C) (75 mg/m2 on day 1) and 5-fluorouracil (F)
Skupaj je bilo zdravljenih 445 bolnikov z oceno zmogljivosti po Karnofskem > 70; prejemali so bodisi docetaksel (T) (75 mg/m2 1. dan) v kombinaciji s cisplatinom (C) (75 mg/m2 1. dan)
General Docetaxel should be administered when the neutrophil count is ≥1,500 cells/mm
Splošno Docetaksel je treba aplicirati, ko je število nevtrofilcev ≥ 1.500 celic/mm
120mg/6 ml contains 6 ml of concentrate.
120 mg/6 ml vsebuje 6 ml koncentrata.
Tabulated list of adverse reactions in breast cancer for adjuvant therapy with Taxespira 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data
Tabelarični prikaz neželenih učinkov adjuvantnega zdravljenja z zdravilom Taxespira 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805) - kumulativni podatki
There was an increased incidence of SAEs (40% vs. 31%) and Grade 4 AEs (34% vs. 23%) in the trastuzumab combination arm compared to docetaxel monotherapy.
V kombinacijski roki s trastuzumabom je prišlo do povečane incidence resnih neželenih učinkov (40 % proti 31 %) in neželenih učinkov stopnje 4 (34 % proti 23 %) v primerjavi z monoterapijo z docetakselom.
This is equivalent to 60 ml of beer or 25 ml of wine.
To ustreza 60 ml piva ali 25 ml vina.
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm. Efficacy endpoints for the docetaxel arms versus the control arm are summarized in the following table:
Povečanje v preživetju opazovano pri roki tedenskega docetaksela ni bilo statistično značilno v primerjavi z mitoksantronovo kontrolno roko zdravljenja.
This is equivalent to 70 ml of beer or 29 ml of wine.
To ustreza 70 ml piva ali 29 ml vina.
Abdominal pain upper; Dry mouth
Bolezni prebavil bolečine v zgornjem delu trebuha, suha usta
• pain in the joints or muscles
• občutek omrtvelosti,mravljinčenjeali bolečine v sklepih ali mišicah
MedDRA System Organ classes
Organski sistemi po MedDRA
This regimen is administered every 3 weeks for 4 cycles.
Ta terapevtska shema se uporablja vsake 3 tedne po 4 cikluse.
Efficacy of docetaxel in the treatment of patients with gastric adenocarcinoma
Učinkovitost docetaksela pri zdravljenju bolnikov z adenokarcinomom želodca končna točka
• indigestion
• nespečnost
Each ml of solution contains 20 mg of docetaxel (as trihydrate).
En ml raztopine vsebuje 20 mg docetaksela (v obliki trihidrata).
Hypotension; Hypertension; Haemorrhage
Žilne bolezni hipotenzija, hipertenzija, krvavitev
Patients with operable node-positive breast cancer (TAX 316) Data from a multicenter open label randomized study support the use of docetaxel for the adjuvant treatment of patients with operable node-positive breast cancer and KPS ≥80%, between 18 and 70 years of age.
Podatki multicentrične, odprte randomizirane študije podpirajo uporabo docetaksela za adjuvantno zdravljenje od 18 do 70 let starih bolnic z operabilnim rakom dojke, pozitivnimi bezgavkami in seštevkom po Karnofskem ≥ 80 %.
120mg/6 ml Each 6 ml vial of concentrate contains 3 ml of ethanol anhydrous (2370 mg).
120 mg/6 ml Ena 6 ml viala koncentrata vsebuje 3 ml brezvodnega etanola (2370 mg).
Patients on the comparator arm received cisplatin (P) 100 mg/m² as a 30-minute to three-hour intravenous infusion on day 1 followed by the continuous intravenous infusion of 5-fluorouracil (F) 1,000 mg/m²/day from day 1 to day 5.
Bolniki v primerjalnem kraku so dobivali cisplatin (P) 100 mg/m2 v 30-minutni do 3-urni intravenski infuziji 1. dan in nato stalno intravensko infuzijo 5-fluorouracila (F) 1000 mg/m2/dan od 1. do 5. dneva.
Best overall response (CR + PR) to chemotherapy (%) (95% CI) ***p-value
Najboljši celotni odziv (CR + PR) na kemoterapijo (%) (95 % IZ) ***Vrednost p
Neutropenic complications
Nevtropenični zapleti
Blood and lymphatic system disorders neutropenia
Bolezni krvi in limfatičnega sistema febrilna nevtropenija
In both arms, after the last cycle of chemotherapy, patients with positive estrogen and/or progesterone receptors received tamoxifen 20 mg daily for up to 5 years.
V obeh krakih so bolnice s pozitivnimi estrogenskimi in/ali progesteronskimi receptorji po zadnjem ciklu kemoterapije do 5 let dobivale tamoksifen 20 mg na dan. Adjuvantna radioterapija je bila predpisana v skladu z veljavnimi smernicami v sodelujočih ustanovah.
What Taxespira looks like and contents of the pack
Izgled zdravila in vsebina pakiranja
Adjuvant radiation therapy was prescribed according to guidelines in place at participating institutions and was given to 69 % of patients who received TAC and 72% of patients who received FAC.
Dobilo jo je 69 % bolnic, ki so prejemale TAC, in 72 % bolnic, ki so prejemale FAC.
• alteration in sense of taste
• spremenjeno okušanje
Patients previously treated with chemotherapy with or without radiotherapy In a phase III study, in previously treated patients, time to progression (12.3 weeks versus 7 weeks) and OS were significantly longer for docetaxel at 75 mg/m² compared to Best Supportive Care.
Bolniki, predhodno zdravljeni s kemoterapijo z radioterapijo ali brez nje V študiji III. študije pri predhodno zdravljenih bolnikih sta bila čas do napredovanja (12,3 tedna v prim.
4.2 Posology and method of administration
4.2 Odmerjanjein način uporabe
Patients with renal impairment There are no data available in patients with severely impaired renal function treated with docetaxel.
Bolniki z okvaro ledvic O zdravljenju z docetakselom pri bolnikih s hudo okvaro ledvic ni podatkov.
Patients with severe liver impairment (see sections 4.2 and 4.4).
Bolniki s hudo okvaro jeter, ker o uporabi pri njih ni podatkov (glejte poglavji 4.2 in 4.4).
Constipation (severe: 0.2%); Abdominal pain (severe: 1%);
zaprtje (hudo 0,2 %), bolečine v trebuhu (hude 1 %), gastrointestinalna krvavitev (huda 0,3 %)
combined with capecitabine at 1250 mg/m2 twice daily (within 30 minutes after a meal) for 2 weeks followed by a 1-week rest period.
V kombinaciji s kapecitabinom je priporočeni odmerek docetaksela 75 mg/m 2 na tri tedne, kombiniran s kapecitabinom 1.250 mg/m2 dvakrat na dan (v 30 minutah po obroku) 2 tedna, čemur sledi 1-tedenski premor.
Gastrointestinal haemorrhage (severe:
vnetje požiralnika (hudo:
Patients on the docetaxel arm received docetaxel (T) 75 mg/m² by intravenous infusion on day 1 followed by cisplatin (P) 100 mg/m² administered as a 30-minute to three-hour intravenous infusion, followed by the continuous intravenous infusion of 5-fluorouracil (F) 1,000 mg/m²/day from day 1 to day 4.
Bolniki v kraku z docetakselom so dobili docetaksel (T) 75 mg/m2 v intravenski infuziji 1. dan, ki mu je sledil cisplatin (P) 100 mg/m2 v 30-minutni do 3-urni intravenski infuziji in nato stalna intravenska infuzija 5fluorouracila (F) 1000 mg/m2/dan od 1. do 4. dneva.
At the end of the follow-up period (actual median follow-up time of 8 years), peripheral oedema was ongoing in 19 TAC patients and 4 FAC patients (0.5%).
Na koncu spremljanja (dejanski mediani čas spremljanja 8 let) je v kraku TAC periferne edeme še vedno imelo 19 bolnic, v kraku FAC pa 4 bolnice (0,5 %).
OS at 10 years was also significantly increased with TAC compared to FAC (76% versus 69%, respectively) i.e. an absolute reduction of the risk of death by 7% (p = 0.002).
Tudi celotno preživetje pri 10 letih je bilo značilno povečano pri TAC v primerjavi z FAC (76 % proti 69 %) t.j.
• muscle aches and pains; back pain or bone pain
• bolečine v mišicah, bolečine v hrbtu ali kosteh
160mg/8 ml Each 8 ml vial of concentrate contains 4 ml of ethanol anhydrous (3160 mg).
160 mg/8 ml Ena 8 ml viala koncentrata vsebuje 4 ml brezvodnega etanola (3160 mg).
• 92 patients treated with docetaxel in combination with trastuzumab.
• 92 bolnicah, ki so prejemale docetaksel v kombinaciji s trastuzumabom.
Dyspepsia (G3/4:
dispepsija (S3/4:
Myocardial ischemia (G3/4:1.7%)
Srčne bolezni miokardna ishemija (S3/4:1,7 %)
Taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.
Zdravilo Taxespira v kombinaciji s cisplatinom je indicirano za zdravljenje neresektabilnega, lokalno napredovalega ali metastatskega nedrobnoceličnega pljučnega raka pri bolnikih, ki zaradi te bolezni še niso dobivali kemoterapije.
Patients should not be retreated with subsequent cycles of docetaxel until neutrophils recover to a level >1,500cells/mm 3 and platelets recover to a level >100,000 cells/mm 3.
Bolniki ne smejo znova dobiti ciklusov docetaksela, dokler se število nevtrofilcev ne poveča na > 1.500 celic/mm
The required volume of Taxespira concentrate for solution for infusion must be injected via a single infusion (one shot) into a 250 ml infusion bag or bottle containing either 5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion.
vbrizgajte v 250-ml infuzijsko vrečko ali steklenico, v kateri je 5 % raztopina glukoze ali raztopina 9 mg/ml (0,9%) natrijevega klorida za infundiranje
80mg/4 ml Each 4 ml vial of concentrate contains 2 ml of ethanol anhydrous (1580 mg).
80 mg/4 ml Ena 4 ml viala koncentrata vsebuje 2 ml brezvodnega etanola (1580 mg).
Patients should be retreated with docetaxel when neutrophils recover to a level ≥ 1,500 cells/mm
Bolniki smejo docetaksel spet dobiti, šele ko se število nevtrofilcev znova zveča na vrednost ≥ 1.500 celic/mm
Distribution Following the administration of a 100 mg/m2 dose given as a one-hour infusion a mean peak plasma level of 3.7 µg/ml was obtained with a corresponding AUC of 4.6 h.µg/ml.
Po aplikaciji odmerka 100 mg/m µg/ml, ustrezna AUC pa 4,6 h.µg/ml.
Physical and chemical in-use stability of the infusion solution prepared as recommended has been demonstrated in non-PVC bags up to 48 hours when stored between 2°C to 8°C.
Dokazano je bilo, da je v skladu z navodili pripravljena infuzijska raztopina v infuzijskih vrečkah, ki ne vsebujejo PVC, med uporabo kemijsko in fizikalno stabilna do 48 ur pri temperaturi od 2-8 °C.
At the end of the follow-up period (actual median follow-up time of 8 years), lymphoedema was observed to be ongoing in 6 TAC patients (0.8%) and 1 FAC patient (0.1%).
Na koncu spremljanja (dejanski mediani čas spremljanja 8 let) so še trajajoč limfedem opažali pri 6 bolnicah v kraku TAC (0,8 %) in pri 1 bolnici v kraku FAC (0,1 %).
This regimen is administered every 3 weeks for 3 cycles.
Ta terapevtska shema se uporablja vsake 3 tedne po 3 cikluse.
How to store Taxespira
Shranjevanje zdravila Taxespira
The onset of moderate and severe retention is delayed (median cumulative dose: 818.9 mg/m2) in patients with premedication compared with patients without premedication (median cumulative dose: 489.7 mg/m2); however, it has been reported in some patients during the early courses of therapy.
Zmeren oz. hud zastoj se kasneje pojavi pri bolnikih, ki dobijo premedikacijo (mediani kumulativni odmerek: 818,9 mg/m2), kot pri tistih, ki je ne
For patients with serum bilirubin levels > ULN and/or ALT and AST >3.5 times the ULN concurrent with serum alkaline phosphatase levels >6 times the ULN, no dose-reduction can be recommended and docetaxel should not be used unless strictly indicated.
Pri bolnikih, ki imajo serumski bilirubin > ULN in/ali ALT in AST > 3,5-kratno ULN ter hkrati alkalno fosfatazo > 6-kratno ULN, ni mogoče priporočiti zmanjšanja odmerka; pri teh bolnikih se docetaksela ne sme uporabljati, če ni strogo indiciran.
There are limited data available in patients >70 years of age on docetaxel use in combination with doxorubicin and cyclophosphamide.
Podatkov o uporabi docetaksela v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah, starih > 70 let, je malo.
Taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
Zdravilo Taxespira v kombinaciji s kapecitabinom je indicirano za zdravljenje bolnic z lokalno napredovalim ali metastatskim rakom dojke po neuspehu citotoksične kemoterapije.
• If you have any further questions, ask your doctor, hospital pharmacist or nurse.
- Če imate dodatna vprašanja, se posvetujte z zdravnikom, bolnišničnimfarmacevtomali medicinsko sestro.
Docetaxel is a substance derived from the needles of yew trees.
Docetaksel je snov, pridobljena iz iglic tise.
After 10 years of follow-up in GEICAM 9805 study, acute leukaemia occurred in 1 of 532 (0.2%)patients in TAC arm. No cases were reported in patients in FAC arm. No patient was diagnosed with myelodysplastic syndrome in either treatment groups.
Po 10 letih spremljanja v študiji GEICAM 9805 se je akutna levkemija pojavila pri 1 od 532 (0,2 %) bolnic v kraku TAC.
In Taxespira 20 mg/1 ml, 80 mg/4 ml, 120 mg/6 ml, 140 mg/7 ml and 160 mg/8 ml vials the concentration of docetaxel is 20 mg/ml.
V vialah zdravila Taxespira 20 mg/1 ml, 80 mg/4 ml, 120 mg/6 ml, 140 mg/7 ml in 160 mg/8 ml je koncentracija docetaksela 20 mg/ ml.